Nektar Therapeutics
NKTR
$0.8968
$0.08149.98%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 42.69% | 42.30% | 57.61% | 25.03% | 35.34% |
| Total Depreciation and Amortization | -38.89% | -37.90% | -38.63% | -40.02% | -29.65% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -113.94% | -100.31% | -97.31% | 88.35% | 20.87% |
| Change in Net Operating Assets | 102.35% | 92.06% | -45.20% | -4,124.39% | 46.41% |
| Cash from Operations | 13.13% | 28.39% | 29.50% | 36.64% | 48.91% |
| Capital Expenditure | -9.30% | 52.41% | 69.10% | 84.76% | 89.69% |
| Sale of Property, Plant, and Equipment | -100.00% | -90.57% | -90.57% | -90.57% | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -32.18% | -46.70% | -55.61% | -61.16% | -67.42% |
| Cash from Investing | -38.51% | -49.33% | -57.19% | -61.85% | -63.63% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -61.16% | -71.90% | -94.21% | -96.04% | -95.08% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -100.00% |
| Cash from Financing | 34,649.59% | 34,638.84% | 7,274.21% | -98.01% | -96.94% |
| Foreign Exchange rate Adjustments | -126.61% | -12.50% | 103.40% | 118.96% | 127.81% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 14.75% | 15.02% | -415.92% | -184.04% | -178.93% |
